AIM ImmunoTech Inc. (AIM)

Develops immuno-therapeutics for the treatment of multiple types of cancers, viral diseases, and immune disorders.

AIM Stock Quote

Company Report

AIM ImmunoTech Inc., an immuno-pharma company based in the United States, specializes in the research and development of innovative therapeutics targeting various cancers, viral diseases, and immune-deficiency disorders. Central to its portfolio is Ampligen, a macromolecular RNA-based drug designed initially for chronic fatigue syndrome (CFS). The company is actively expanding Ampligen's applications to include treatments for renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

In addition to Ampligen, AIM ImmunoTech offers Alferon N Injection, an injectable formulation of natural alpha interferon used in the treatment of genital warts, a sexually transmitted disease. The company collaborates extensively through agreements with UMN Pharma Inc., Japanese National Institute of Infectious Diseases, Shionogi & Co., Ltd., Polysciences Inc., and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente, enhancing its research capabilities and strategic partnerships.

Founded in 1966 and headquartered in Ocala, Florida, AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.) has a rich history of pioneering advancements in immunotherapy. With a focus on leveraging RNA-based technologies to combat complex diseases, the company remains committed to advancing novel treatments that address significant unmet medical needs globally.

AIM EPS Chart

AIM Revenue Chart

Stock Research

KEX JCI TPR SGMO NIC WST VALU

AIM Chart

View interactive chart for AIM

AIM Profile

AIM News

Analyst Ratings